primeCROWD Record investment: EUR 2 million for acquisition of Molzym by Gradian Diagnostics

primeCROWD Record investment: EUR 2 million for acquisition of Molzym by Gradian Diagnostics

Datum: 2020-02-10 15:11:35

Success Story

primeCROWD Record investment: EUR 2 million for acquisition of Molzym by Gradian Diagnostics

Vienna/Bremen/Miami: With our network of start-up investors, we were able to complete the successful acquisition of Molzym GmbH & Co. KG, a manufacturer of molecular diagnostic products based in Bremen, by Gradian Diagnostics from Miami. In total, international investors from our network invested 2 million euros. 

We see Molzym as a company that is an absolute technological leader. With our investment, this technological leadership should now be used above all to scale up considerably in the relevant markets. With Gabriel Tirouflet, an experienced MedTech CEO is taking the helm and thus now primarily the position of Head of Sales. His good relations to the French market, coupled with Alex Malbran's important connections in the USA and Latin America have convinced us to present Gradian/Molzym to our network.Molzym was founded in 2003 in

Bremen, Germany, where the team of twenty researchers is developing a product that saves lives through the speed and precision of its diagnoses. The Med Tech company specializes in solutions for molecular microbiology research and routine microbial pathogen diagnostics. Its customers include many of the world's leading hospitals and laboratories. The most important development is a diagnostic method that makes it possible to identify bacteria more quickly in the case of blood poisoning (sepsis). 

Our CEO Markus Kainz is quite proud of this transaction, as it represents a new record:

"primeCROWD investors have invested 1.9 million Euros in this deal. This is the highest amount of financing ever raised for an investment from our network".

Prof. Michael Lorenz, founder of Molzym, is also very satisfied with the deal:

"Molzym and Gradian Diagnostics are a perfect match. We share the same values and pursue the same goals. As a leading company in microbial molecular diagnostics, we wanted to find trustworthy partners with whom we can work together to offer an even more comprehensive service while maintaining our focus. As part of Gradian Diagnostics, we can accelerate our growth and now have a foothold in the US.